NasdaqGS - Delayed Quote • USD
Editas Medicine, Inc. (EDIT)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 6:22 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
78,123.00
78,123.00
19,712.00
25,544.00
90,732.00
Operating Expense
247,304.00
247,304.00
245,662.00
218,690.00
225,572.00
Operating Income
-169,181.00
-169,181.00
-225,950.00
-193,146.00
-134,840.00
Net Non Operating Interest Income Expense
17,566.00
17,566.00
5,518.00
607.00
2,605.00
Other Income Expense
-1,604.00
-1,604.00
1,293.00
37.00
16,259.00
Pretax Income
-153,219.00
-153,219.00
-220,432.00
-192,502.00
-115,976.00
Net Income Common Stockholders
-153,219.00
-153,219.00
-220,432.00
-192,502.00
-115,976.00
Diluted NI Available to Com Stockholders
-153,219.00
-153,219.00
-220,432.00
-192,502.00
-115,976.00
Basic EPS
-2.69
-2.02
-3.21
-2.85
-1.98
Diluted EPS
-2.69
-2.02
-3.21
-2.85
-1.98
Basic Average Shares
72,720.88
75,965.63
68,664.82
67,619.39
58,609.39
Diluted Average Shares
72,720.88
75,965.63
68,664.82
67,619.39
58,609.39
Total Operating Income as Reported
-169,181.00
-169,181.00
-225,950.00
-193,146.00
-134,840.00
Total Expenses
247,304.00
247,304.00
245,662.00
218,690.00
225,572.00
Net Income from Continuing & Discontinued Operation
-153,219.00
-153,219.00
-220,432.00
-192,502.00
-115,976.00
Normalized Income
-153,219.00
-153,219.00
-220,432.00
-192,502.00
-115,976.00
Interest Income
17,566.00
17,566.00
5,518.00
607.00
2,605.00
Net Interest Income
17,566.00
17,566.00
5,518.00
607.00
2,605.00
EBIT
-169,181.00
-169,181.00
-225,950.00
-193,146.00
-134,840.00
EBITDA
-163,117.00
-163,117.00
-219,613.00
-188,093.00
-130,881.00
Reconciled Depreciation
6,064.00
6,064.00
6,337.00
5,053.00
3,959.00
Net Income from Continuing Operation Net Minority Interest
-153,219.00
-153,219.00
-220,432.00
-192,502.00
-115,976.00
Normalized EBITDA
-163,117.00
-163,117.00
-219,613.00
-188,093.00
-130,881.00
12/31/2020 - 2/3/2016
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NTLA Intellia Therapeutics, Inc.
20.76
+3.70%
BEAM Beam Therapeutics Inc.
21.38
-1.02%
CRSP CRISPR Therapeutics AG
53.91
+0.34%
CRBU Caribou Biosciences, Inc.
3.7100
-1.33%
VERV Verve Therapeutics, Inc.
6.16
-0.96%
BLUE bluebird bio, Inc.
0.9228
+1.13%
PRME Prime Medicine, Inc.
4.4250
+2.91%
FATE Fate Therapeutics, Inc.
3.8000
-1.81%
RXRX Recursion Pharmaceuticals, Inc.
8.12
+3.57%
IOVA Iovance Biotherapeutics, Inc.
11.64
+0.87%